Literature DB >> 2545341

DNA topoisomerase I-mediated DNA cleavage and cytotoxicity of camptothecin analogues.

Y H Hsiang1, L F Liu, M E Wall, M C Wani, A W Nicholas, G Manikumar, S Kirschenbaum, R Silber, M Potmesil.   

Abstract

20(S)-Camptothecin, the 20(S)-camptothecin sodium salt, and 12 analogues with substituents on the A ring differ widely in their effectiveness in the treatment of murine L1210 lymphoblastic leukemia in vivo. The drugs were screened in the following systems: System 1, the cleavage of DNA in the presence of purified topoisomerase I; System 2, drug-induced trapping of topoisomerase I in a covalent complex with DNA; and System 3, the induction of protein-associated DNA breaks in drug-treated L1210 leukemia cells. 9-Amino-20(S), 10-amino-20(RS), and 10,11-methylenedioxy-20(RS), drugs effective against murine L1210 leukemia in vivo, stabilize topoisomerase I-DNA cleavable complexes in a purified system and in cultured L1210 cells. Other analogues, inactive against L1210 leukemia in vivo, were totally ineffective in topoisomerase I-directed screens. The rest of the analogues were intermediate in terms of their antitumor and topoisomerase I-directed activities. The study shows that the drug-induced accumulation of enzyme-DNA cleavable complexes is directly proportional to drug cytotoxicity and antitumor activity.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2545341

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  53 in total

1.  The mechanism of topoisomerase I poisoning by a camptothecin analog.

Authors:  Bart L Staker; Kathryn Hjerrild; Michael D Feese; Craig A Behnke; Alex B Burgin; Lance Stewart
Journal:  Proc Natl Acad Sci U S A       Date:  2002-11-08       Impact factor: 11.205

Review 2.  DNA topoisomerases and their poisoning by anticancer and antibacterial drugs.

Authors:  Yves Pommier; Elisabetta Leo; HongLiang Zhang; Christophe Marchand
Journal:  Chem Biol       Date:  2010-05-28

3.  Comparative molecular field analysis and molecular modeling studies of 20-(S)-camptothecin analogs as inhibitors of DNA topoisomerase I and anticancer/antitumor agents.

Authors:  S W Carrigan; P C Fox; M E Wall; M C Wani; J P Bowen
Journal:  J Comput Aided Mol Des       Date:  1997-01       Impact factor: 3.686

4.  Metabolic pathways of the camptothecin analog AR-67.

Authors:  Jamie Horn; Marta Milewska; Susanne M Arnold; Markos Leggas
Journal:  Drug Metab Dispos       Date:  2010-12-28       Impact factor: 3.922

Review 5.  Clinical pharmacokinetics of irinotecan.

Authors:  G G Chabot
Journal:  Clin Pharmacokinet       Date:  1997-10       Impact factor: 6.447

6.  Irinotecan plus cisplatin combination against metastatic gastric cancer: phase II study.

Authors:  Mustafa Altinbas; Ozlem Er; Metin Ozkan; Yusuf Solak; H Senol Coskun; Can Kucuk; Sebnem Gursoy
Journal:  Med Oncol       Date:  2005       Impact factor: 3.064

Review 7.  Tyrosyl-DNA-phosphodiesterases (TDP1 and TDP2).

Authors:  Yves Pommier; Shar-yin N Huang; Rui Gao; Benu Brata Das; Junko Murai; Christophe Marchand
Journal:  DNA Repair (Amst)       Date:  2014-05-22

Review 8.  Pharmacogenomics in colorectal cancer: the first step for individualized-therapy.

Authors:  Eva Bandrés; Ruth Zárate; Natalia Ramirez; Ana Abajo; Nerea Bitarte; Jesus Garíia-Foncillas
Journal:  World J Gastroenterol       Date:  2007-11-28       Impact factor: 5.742

9.  Stable supersaturated aqueous solutions of silatecan 7-t-butyldimethylsilyl-10-hydroxycamptothecin via chemical conversion in the presence of a chemically modified beta-cyclodextrin.

Authors:  Tian-Xiang Xiang; Bradley D Anderson
Journal:  Pharm Res       Date:  2002-08       Impact factor: 4.200

10.  Synthesis and biological evaluation of 14-(aminoalkyl-aminomethyl)aromathecins as topoisomerase I inhibitors: investigating the hypothesis of shared structure-activity relationships.

Authors:  Maris A Cinelli; Brenda Cordero; Thomas S Dexheimer; Yves Pommier; Mark Cushman
Journal:  Bioorg Med Chem       Date:  2009-09-06       Impact factor: 3.641

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.